Going beyond the median: estimating survival times for patients with hormone receptor positive, metastatic breast cancer commencing endocrine therapy

Andrew O. Parsonson; Sunit Sarkar; Lauren Brown; Belinda Kiely; Anuradha Vasista

doi:10.1158/1538-7445.SABCS22-P3-01-10

Going beyond the median: estimating survival times for patients with hormone receptor positive, metastatic breast cancer commencing endocrine therapy

Andrew O. Parsonson, Sunit Sarkar, Lauren Brown, Belinda Kiely, Anuradha Vasista

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	P3-01-10
Number of pages	2
Journal	Cancer Research
Volume	83
Issue number	5 Supplement
DOIs	https://doi.org/10.1158/1538-7445.SABCS22-P3-01-10
Publication status	Published - 1 Mar 2023
Externally published	Yes
Event	2022 San Antonio Breast Cancer Symposium - San Antonio, United States Duration: 6 Dec 2022 → 10 Dec 2022

Access to Document

10.1158/1538-7445.SABCS22-P3-01-10

Cite this

@article{826844bb65554ef5821f92c51c295acf,

title = "Going beyond the median: estimating survival times for patients with hormone receptor positive, metastatic breast cancer commencing endocrine therapy",

author = "Parsonson, {Andrew O.} and Sunit Sarkar and Lauren Brown and Belinda Kiely and Anuradha Vasista",

year = "2023",

month = mar,

day = "1",

doi = "10.1158/1538-7445.SABCS22-P3-01-10",

language = "English",

volume = "83",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "5 Supplement",

note = "2022 San Antonio Breast Cancer Symposium ; Conference date: 06-12-2022 Through 10-12-2022",

}

TY - JOUR

T1 - Going beyond the median

T2 - 2022 San Antonio Breast Cancer Symposium

AU - Parsonson, Andrew O.

AU - Sarkar, Sunit

AU - Brown, Lauren

AU - Kiely, Belinda

AU - Vasista, Anuradha

PY - 2023/3/1

Y1 - 2023/3/1

U2 - 10.1158/1538-7445.SABCS22-P3-01-10

DO - 10.1158/1538-7445.SABCS22-P3-01-10

M3 - Meeting abstract

SN - 0008-5472

VL - 83

JO - Cancer Research

JF - Cancer Research

IS - 5 Supplement

M1 - P3-01-10

Y2 - 6 December 2022 through 10 December 2022

ER -